Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do

埃克斯塞勒科学公司筹集9500万美元，利用机器可操作的新型化学技术，变革小分子发现与制造。

• Deerfield Management, Khosla Ventures, and Sofinnova Partners co-lead Series A fundraise for Excelsior Sciences to accelerate drug discovery and clinical development while supporting pharma reshoring.

• Deerfield Management、Khosla Ventures 和 Sofinnova Partners 联合领投 Excelsior Sciences 的 A 轮融资，以加速药物发现和临床开发，同时支持制药业回流。

NEW YORK, December 3, 2025-- Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules..

纽约，2025年12月3日——Excelsior Sciences是一家致力于开发一种机器可执行、人工智能可利用以实现闭环药物发现的新型化学技术的公司，今天宣布已筹集9500万美元，以加速其重塑小分子发现与制造流程的使命。

The financing includes a $70 million Series A, co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, as well as a $25 million grant from New York’s Empire State Development. Other participants include Cornucopian Capital, Eli Lilly and Company, Illinois Ventures, and the leading academic institution, MIT..

融资包括由Deerfield Management、Khosla Ventures和Sofinnova Partners共同领投的7000万美元A轮融资，以及来自纽约州Empire State Development的2500万美元拨款。其他参与者包括Cornucopian Capital、Eli Lilly and Company、Illinois Ventures以及领先的学术机构麻省理工学院（MIT）。

A Novel Approach for Small Molecule Science

小分子科学的新方法

Small molecules, the class of chemical matter primarily built from carbon-carbon bonds, perform countless essential functions in our lives: they are central to our life-saving drugs, manufacturing materials, veterinary and agricultural products, and much more. While AI has the potential to transform these fields, it requires the ability to make and test new small molecules in multiple assays fast enough to feed data-hungry algorithms..

小分子，主要由碳-碳键构成的化学物质类别，在我们的生活中发挥着无数至关重要的功能：它们是我们救命药物、制造材料、兽医和农业产品等的核心。尽管人工智能有潜力改变这些领域，但它需要能够快速在多种测试中制造和测试新的小分子，以满足数据饥渴的算法需求。

Earlier attempts to automate chemistry have failed because they replicate the traditional artisanal approach to chemical synthesis. By contrast, Excelsior Sciences has created a proprietary form of chemistry that machines can do. At the heart of this innovation are smart bloccs—automated synthesis-friendly chemical building blocks that enable iterative carbon–carbon bond formation.

早期试图将化学自动化的方法失败了，因为它们复制了传统的手工艺方法来进行化学合成。相比之下，Excelsior Sciences 创造了一种专有的、机器可执行的化学形式。这一创新的核心是智能模块——自动化合成友好的化学构建块，能够实现迭代的碳-碳键形成。

Smart bloccs serve as a modular chemical “language,” allowing AI to derive novel insights and guide discovery in closed-loop learning systems..

智能块作为一种模块化的化学“语言”，允许人工智能在闭环学习系统中得出新的见解并指导发现。

“Drug discovery and manufacturing are at a crossroads in the West. To stay competitive, we must discover and develop better medicines—faster. This can only be achieved through automated synthesis platforms capable of rapidly producing purified compounds and testing them across multiple assays simultaneously—generating the rich data AI needs to cut years off traditional discovery timelines,” said Michael Foley, PhD, co-founder and CEO of Excelsior Sciences.

“西方的药物发现和制造正处于十字路口。为了保持竞争力，我们必须更快地发现和开发更好的药物。只有通过自动化的合成平台才能实现这一目标，该平台能够快速生产纯化化合物并在多个测试中同时进行检测——为人工智能提供所需的数据，从而大幅缩短传统的药物发现时间线。” Excelsior Sciences 的联合创始人兼首席执行官 Michael Foley 博士说道。

“Our proprietary smart bloccs platform is the first system to seamlessly integrate discovery and scale-up chemistry, enabling the reshoring of drug discovery and manufacturing. We are starting with drug discovery but will work across multiple sectors.”.

“我们专有的智能区块平台是首个无缝集成发现和放大化学的系统，能够实现药物发现和制造的回流。我们将从药物发现开始，但会跨多个领域开展工作。”

The Reshoring Imperative

重归本土化的必要性

Excelsior’s launch comes at a pivotal time for the pharmaceutical industry, which is under pressure to secure supply chains and reshore more of its discovery and manufacturing capabilities. The United States’ overreliance on offshoring for the discovery and manufacturing of the nation’s drug supply represents a major strategic vulnerability—one the pharma industry is committing upwards of $250 billion to address..

Excelsior 的推出正值制药行业的关键时刻，该行业面临确保供应链安全并将更多研发和制造能力迁回本土的压力。美国过度依赖海外资源进行药品研发和生产，这代表了一个重大的战略漏洞——制药行业正投入高达 2500 亿美元来解决这一问题。

Excelsior Sciences aims to make reshoring affordable for both discovery and manufacturing, providing strategic immunity to nations whose pharma supply chains are vulnerable to sudden geopolitical shifts.

永攀科学公司旨在使发现和制造的回流变得可负担，为那些制药供应链容易受到地缘政治突变影响的国家提供战略免疫力。

“The idea that sparked Excelsior arose via the company-building relationship Deerfield cultivated with Dr. Marty Burke, whose lab at the University of Illinois discovered and patented the insights that power the smart blocc technology,” said Jim Flynn, Managing Partner at Deerfield. “We view Excelsior’s applications to drug discovery and manufacturing as transformational, and we are pleased to have attracted such strong syndicate partners to advance what we have begun.”.

“激发Excelsior想法的灵感源于Deerfield与Marty Burke博士之间建立的公司合作关系，Burke博士在伊利诺伊大学的实验室发现了推动智能阻断技术的见解并申请了专利，”Deerfield的管理合伙人Jim Flynn表示。“我们认为Excelsior在药物发现和制造中的应用具有变革性，我们很高兴吸引了如此强大的财团合作伙伴来推进我们已经开始的工作。”

Building the Future of AI-powered Chemistry

构建人工智能驱动的化学未来

This Series A financing will support Excelsior as it scales its smart bloccs platform and demonstrates its ability to revolutionize the discovery and manufacture of small molecules. Excelsior Sciences will also invest in its internal pipeline and build partnerships across a range of industry sectors, including therapeutics and materials science..

本轮融资将支持 Excelsior 扩展其智能模块平台，并展示其彻底改变小分子发现和制造的能力。Excelsior Sciences 还将投资于内部管线，并在包括治疗学和材料科学在内的一系列行业领域建立合作关系。

“Everyone’s talking about AI-designed drugs, but they cannot become a reality without scalable chemistry. Excelsior is the missing piece. They’ve built the right chemistry for the AI era, where design, synthesis, and testing happen in a closed loop. It’s turning theory into tangible molecules and real medicine.

“每个人都在谈论人工智能设计的药物，但没有可扩展的化学技术，它们无法成为现实。Excelsior 就是缺失的一环。他们为人工智能时代构建了正确的化学体系，设计、合成和测试在一个闭环中进行。这正在将理论转化为实际的分子和真正的药物。”

That’s why we backed this exceptional team as part of the Sofinnova Digital Medicine strategy,” said Edward Kliphuis, Partner at Sofinnova Partners..

“这就是为什么我们作为 Sofinnova 数字医学战略的一部分支持这个非凡的团队，” Sofinnova Partners 合伙人 Edward Kliphuis 表示。

“Excelsior is closing the gap between what AI can model in theory and what chemistry can make in the real world,” said Nessan Bermingham of Khosla Ventures. “Being able to manufacture small molecules this way opens the door to breakthroughs in new medicines and materials science, and it’s a critically strategic capability to build here in the U.S.”.

“Excelsior 正在缩小人工智能在理论上可以模拟的内容与化学在现实世界中可以制造的内容之间的差距，”Khosla Ventures 的 Nessan Bermingham 表示。“能够以这种方式制造小分子，为新药和材料科学的突破打开了大门，而且这是一项在美国建立的关键战略性能力。”

Empire State Development President, CEO and Commissioner Hope Knight said, “Excelsior Sciences exemplifies how New York continues to attract companies redefining the frontiers of life sciences. Their technology will help address one of the most pressing challenges in American pharmaceutical manufacturing—securing domestic drug supply chains—while establishing our state as a leader in AI-powered chemistry and advanced manufacturing.

帝国州发展局总裁、首席执行官兼专员霍普·奈特表示：“卓越科学公司展示了纽约如何继续吸引重新定义生命科学前沿的公司。他们的技术将有助于应对美国制药生产领域最紧迫的挑战之一——确保国内药物供应链的安全，同时确立我们州在人工智能驱动的化学和先进制造领域的领导地位。”

Empire State Development is proud to support their work as they help shape the future of scientific discovery and production in New York.”.

帝国州发展局自豪地支持他们的工作，因为他们帮助塑造纽约科学发现和生产的未来。

Spun out of Deerfield Management and housed in custom-built laboratory space at Cure in New York City, Excelsior is co-founded by Michael Foley, PhD, Marty Burke, MD, PhD, Bartosz Grzybowski, PhD, and Jana Jensen, PhD, MBA, reflecting the company’s marriage of AI and chemistry.

Excelsior 由 Deerfield Management 分拆出来，并在纽约市 Cure 的定制实验室空间内设立，由迈克尔·福利博士、马蒂·伯克医学博士、博士、巴托什·格日博夫斯基博士和雅娜·延森博士、工商管理硕士共同创立，体现了这家公司人工智能与化学的结合。

Organizations, institutions or researchers wishing to register interest in becoming an Excelsior Sciences partner should contact the team at: partnering@excelsiorsci.com.

希望注册成为Excelsior Sciences合作伙伴的组织、机构或研究人员应通过以下方式联系团队：partnering@excelsiorsci.com。

For media inquiries, please contact the press office (details below).

媒体查询，请联系新闻办公室（详情如下）。

About Excelsior Sciences

关于卓越科学

Excelsior Sciences is revolutionizing small molecule innovation. The company is developing a new form of chemistry that machines can do and AI can use to accelerate the discovery and manufacture of small molecules. The company’s unique smart blocc approach quickly creates molecular solutions from automated synthesis-friendly, function-infused, and AI-readable building blocks.

恒星科学公司正在彻底改变小分子创新。该公司正在开发一种机器可以执行并人工智能可以用来加速小分子发现和制造的新型化学。公司独特的智能积木方法能够快速从自动化合成友好、功能注入且人工智能可读的构建模块中创建分子解决方案。

These smart bloccs serve as tokens in a modular chemical “language” that enables AI to accelerate discovery and manufacturing, derive novel insights, and define new functional frontiers for an array of industries and applications..

这些智能模块作为模块化化学“语言”中的令牌，使人工智能能够加速发现和制造、得出新颖的见解，并为众多行业和应用定义新的功能前沿。

Excelsior Sciences is the only company built on a proven, published track record of making real-world advances in multiple fields using automated small molecule synthesis coupled with AI, with the goal to spark an innovation renaissance of safer, more effective, and more sustainable solutions to human and planetary challenges.

永攀科学公司是唯一一家基于经过验证并已发表的业绩记录而建立的公司，该公司利用自动化小分子合成与人工智能相结合，在多个领域实现了现实世界的进步，其目标是激发一场创新复兴，为人类和地球面临的挑战提供更安全、更有效和更可持续的解决方案。

For more information, please visit: excelsiorsci.com..

欲了解更多信息，请访问：excelsiorsci.com。

About Empire State Development

关于帝国州发展中心

Empire State Development is New York's chief economic development agency, and promotes business growth, job creation, and greater economic opportunity throughout the state. With offices in each of the state's 10 regions, ESD oversees the Regional Economic Development Councils, supports broadband equity through the ConnectALL office, and is growing the workforce of tomorrow through the Office of Strategic Workforce Development.

纽约州经济发展厅是纽约州主要的经济发展机构，致力于促进全州的商业增长、就业创造和更大的经济机会。经济发展厅在该州的10个地区均设有办事处，负责监督区域经济发展委员会，通过ConnectALL办公室支持宽带公平，并通过战略劳动力发展办公室培养未来的劳动力。

The agency engages with emerging and next generation industries like clean energy and semiconductor manufacturing looking to grow in New York State, operates a network of assistance centers to help small businesses grow and succeed, and promotes the state's world class tourism destinations through I LOVE NY.

该机构与清洁能源和半导体制造等新兴和下一代产业合作，寻求在纽约州发展，运营着一个帮助小企业成长和成功的援助中心网络，并通过“我爱纽约”推广该州的世界级旅游目的地。

For more information, please visit esd.ny.gov, and connect with ESD on LinkedIn, Facebook and X..

欲了解更多信息，请访问 esd.ny.gov，并在 LinkedIn、Facebook 和 X 上与 ESD 联系。

About Sofinnova Partners

关于索菲诺瓦合伙人

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage..

索芬诺瓦合伙公司是欧洲领先的生命科学风险投资公司，专注于医疗保健和可持续性。公司总部位于巴黎、伦敦和米兰，汇聚了一支来自世界各地的专业团队，拥有强大的科学、医学和商业专业知识。索芬诺瓦合伙公司是一家全程参与的公司建设者，覆盖生命科学投资的整个价值链，从种子阶段到后期阶段。

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com..

成立于1972年的 Sofinnova Partners 是一家在欧洲根基深厚的风投公司，拥有50年的经验，支持过500多家公司，并在全球范围内打造了市场领军企业。如今，Sofinnova Partners 管理着超过40亿欧元的资产。欲了解更多信息，请访问：sofinnovapartners.com。

About Khosla Ventures

关于科斯拉创投

Khosla Ventures is a venture capital firm focused on investments in artificial intelligence, financial services, healthcare, consumer, enterprise, and sustainability. It is known for making early capital investments in startups such as OpenAI, Guardant Health, Instacart, Affirm, DoorDash, and Block..

Khosla Ventures 是一家风险投资公司，专注于人工智能、金融服务、医疗保健、消费、企业和可持续发展领域的投资。该公司以对 OpenAI、Guardant Health、Instacart、Affirm、DoorDash 和 Block 等初创公司进行早期资本投资而闻名。

About Deerfield Management

德菲尔德管理公司简介

Deerfield is an investment management firm committed to advancing healthcare through investment, intelligence, and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit www.deerfield.com..

Deerfield是一家投资管理公司，致力于通过投资、智慧和慈善事业推动医疗保健的发展。该公司在医疗保健生态系统中开展工作，以大胆、协作和包容的方式连接人才、资本、创意和技术。欲了解更多信息，请访问www.deerfield.com。

Contact:

联系：

Media Contact

媒体联系人

excelsiorsciences@yourstorypr.com

卓越科学@yourstorypr.com